Keystone Symposia Annual Meeting Series on Obesity

描述（由申请人提供）：要求支持一系列关于肥胖主题的年度Keystone专题会议。该系列的第一次会议将于2015年举行，题为“肥胖和代谢综合征：线粒体和能量消耗”，由Johan Auwerx、Eleftheria Maratos-Flier和Thomas Langer组织。会议将于2015年3月22日至27日在加拿大不列颠哥伦比亚省惠斯勒举行。21世纪的一项医学挑战是预期寿命的空前增加与慢性多因素疾病的发病率和流行率的大幅增加相结合。典型的疾病例子包括代谢紊乱，如肥胖和2型糖尿病，它们通常与非酒精性肝病和冠状动脉、外周血管和中枢性血管疾病等合并症有关。这些疾病通常统称为代谢综合征。在过去的十年中，很明显，细胞代谢的变化通常与线粒体数量、形态和功能的变化有关，并且这些细胞变化是代谢综合征许多临床特征的系统性代谢异常的基础。Keystone座谈会2015年肥胖与代谢综合征会议将讨论外周组织（如肝脏、肌肉和肠道）线粒体功能与代谢综合征系统性异常之间联系的新发现。本文将对基于线粒体功能改变的新疗法的潜力进行综述。由于线粒体功能现在被认为除了在细胞水平上控制能量稳态外，还在有机体水平上控制代谢稳态，本次会议将创造一个真正的跨学科环境，汇集生物能量学领域的基础科学家，

DESCRIPTION (provided by applicant): Support is requested for a series of annual Keystone Symposia meetings on the topic of Obesity. The first meeting in the series will be held in 2015 and is entitled Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure, and is being organized by Johan Auwerx, Eleftheria Maratos-Flier and Thomas Langer. The meeting will be held in Whistler, British Columbia, Canada from March 22-27, 2015. A medical challenge of the 21st century is the coupling of an unprecedented increase in life expectancy with a large increase in incidence and prevalence of chronic multifactorial diseases. Classic disease examples include disorders of metabolism such as obesity and type 2 diabetes mellitus, which are often associated with co- morbidities including non-alcoholic liver disease and coronary, peripheral and central vascular disease. Collectively the spectrum of disorders is often referred to as the metabolic syndrome. Over the past decade, it has become evident that shifts in cellular metabolism are often linked to changes in the number, morphology, and function of mitochondria, and that these cellular changes underlie systemic metabolic abnormalities that characterize the many clinical features of the metabolic syndrome. Keystone Symposia's 2015 meeting on Obesity and the Metabolic Syndrome will discuss novel findings that link mitochondrial function in peripheral tissues, such as liver, muscle and gut, with the systemic abnormalities of the metabolic syndrome. The potential for identifying new therapeutics that are based on modifying mitochondrial function will be reviewed. As mitochondrial function is now acknowledged to also control metabolic homeostasis on an organismal level in addition to controlling energy homeostasis at the cellular level this meeting will create a truly interdisciplinary environment that brings together basic scientists in the fields of bioenergetics, mitochondrial and cell biology, physiology and clinicians with an interest in metabolic disease, to foster innovative ideas in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Liver Metabolism and Nonalcoholic Fatty Liver Disease, which will share a plenary session with this meeting.